Canada Post Corp Registered Pension Plan Acquires 22,986 Shares of Bristol Myers Squibb Company $BMY

Canada Post Corp Registered Pension Plan grew its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY) by 35.9% in the fourth quarter, HoldingsChannel reports. The fund owned 87,063 shares of the biopharmaceutical company’s stock after purchasing an additional 22,986 shares during the quarter. Canada Post Corp Registered Pension Plan’s holdings in Bristol Myers Squibb were worth $4,696,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently made changes to their positions in the company. Physician Wealth Advisors Inc. grew its stake in shares of Bristol Myers Squibb by 73.5% during the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 202 shares during the period. Darwin Wealth Management LLC bought a new position in shares of Bristol Myers Squibb during the 2nd quarter valued at approximately $25,000. EQ Wealth Advisors LLC bought a new position in shares of Bristol Myers Squibb during the 4th quarter valued at approximately $32,000. Garner Asset Management Corp bought a new position in shares of Bristol Myers Squibb during the 4th quarter valued at approximately $35,000. Finally, Beacon Financial Strategies CORP bought a new position in shares of Bristol Myers Squibb during the 4th quarter valued at approximately $38,000. 76.41% of the stock is currently owned by institutional investors.

Bristol Myers Squibb Trading Up 0.5%

BMY stock opened at $57.04 on Friday. Bristol Myers Squibb Company has a 1-year low of $42.52 and a 1-year high of $62.89. The company has a debt-to-equity ratio of 2.10, a current ratio of 1.42 and a quick ratio of 1.28. The company has a market capitalization of $116.48 billion, a price-to-earnings ratio of 16.02, a PEG ratio of 0.16 and a beta of 0.26. The business has a 50 day simple moving average of $58.63 and a two-hundred day simple moving average of $55.35.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, beating the consensus estimate of $1.42 by $0.16. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The business had revenue of $11.49 billion during the quarter, compared to the consensus estimate of $10.93 billion. During the same quarter in the prior year, the firm earned $1.80 EPS. The business’s revenue was up 2.6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Research analysts anticipate that Bristol Myers Squibb Company will post 6.31 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, May 1st. Shareholders of record on Thursday, April 2nd were issued a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 4.4%. The ex-dividend date of this dividend was Thursday, April 2nd. Bristol Myers Squibb’s dividend payout ratio is 70.79%.

Analysts Set New Price Targets

Several research analysts recently weighed in on the stock. Piper Sandler reaffirmed an “overweight” rating and issued a $75.00 target price (up from $66.00) on shares of Bristol Myers Squibb in a report on Monday, February 23rd. Bank of America dropped their target price on shares of Bristol Myers Squibb from $68.00 to $67.00 and set a “buy” rating for the company in a report on Thursday, April 9th. Wall Street Zen raised shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Sunday, April 19th. Royal Bank Of Canada assumed coverage on shares of Bristol Myers Squibb in a report on Tuesday, February 24th. They issued a “sector perform” rating and a $60.00 target price for the company. Finally, Morgan Stanley reaffirmed an “underweight” rating and issued a $40.00 target price on shares of Bristol Myers Squibb in a report on Friday, February 6th. Eight investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $61.31.

Insider Activity at Bristol Myers Squibb

In other Bristol Myers Squibb news, EVP David V. Elkins sold 30,000 shares of the stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the completion of the transaction, the executive vice president owned 159,248 shares of the company’s stock, valued at $9,820,824.16. This represents a 15.85% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.05% of the stock is owned by company insiders.

Key Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb’s $15.2 billion collaboration and licensing deal with Hengrui Pharma expands its pipeline with 13 early-stage programs, a major long-term growth catalyst. Bristol-Myers Strikes $15.2 Billion China Drug Deal
• Positive Sentiment: Zacks Research raised earnings estimates for FY2026, FY2027, FY2028 and several quarterly periods, suggesting improved profitability expectations for BMY. MarketBeat Bristol Myers Squibb estimates update
• Positive Sentiment: Tempus expanded its strategic collaboration with Bristol Myers Squibb to use AI and real-world data to improve clinical development success in oncology and neuroscience. Tempus expands strategic collaboration with Bristol Myers Squibb
• Positive Sentiment: Tigerlily Foundation announced a collaboration with Bristol Myers Squibb to expand clinical trial access and reduce participation barriers, supporting the company’s ESG and patient-access profile. Tigerlily Foundation collaborates with Bristol Myers Squibb
• Neutral Sentiment: Bristol Myers Squibb presented at the Bank of America Global Healthcare Conference, which is typically informational rather than a direct stock-moving event. Bristol-Myers Squibb Company presents at conference transcript
• Neutral Sentiment: Analyst commentary on BMY’s valuation and “buy, sell, or hold” status adds context, but it does not appear to be a new fundamental catalyst. Bristol-Myers Squibb buy sell or hold post Q1 earnings
• Negative Sentiment: One article highlighted a recent pullback in BMY shares, reminding investors that momentum has been uneven despite the recent rally. Bristol-Myers Squibb Stock Falls 3.9% After May 2026 Pullback

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late?stage pipeline reflect a strong emphasis on cancer and immune?mediated conditions.